预约演示
更新于：2026-04-03
Lubiprostone
鲁比前列酮
更新于：2026-04-03
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2006-01-31), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32F2O5 |
InChIKeyWGFOBBZOWHGYQH-MXHNKVEKSA-N |
CAS号333963-40-9 |
关联
85
项与 鲁比前列酮 相关的临床试验NCT07405736
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer, A Randomized Controlled Phase II Study
NCT07277907
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation: A Multicenter, Randomized Controlled Trial
ChiCTR2500112886
Comparison of Polyethylene Glycol Combined with Lubiprostone versus Standard-Dose Polyethylene Glycol for Bowel Preparation Before Colonoscopy in Patients with Chronic Constipation: A Multicenter Randomized Controlled Trial
100 项与 鲁比前列酮 相关的临床结果
登录后查看更多信息
100 项与 鲁比前列酮 相关的转化医学
登录后查看更多信息
100 项与 鲁比前列酮 相关的专利（医药）
登录后查看更多信息
434
项与 鲁比前列酮 相关的文献（医药）2026-03-01AMERICAN JOURNAL OF GASTROENTEROLOGY
The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Review
作者: Busam, Jonathan A. ; Pimentel, Mark ; Rezaie, Ali ; Marshall, Caroline ; Joo, LiJin ; Batta, Nisha ; Shah, Eric D.
INTRODUCTION::
Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, could enable more comprehensive risk-benefit assessments.
METHODS::
PubMed, Web of Science, and Cochrane databases were searched through October 2024. Clinical trials investigating IBS pharmacotherapies including discontinuation rates because of adverse events (AEs) were included. Data were pooled using a random-effects model. The primary outcome was NNH for each pharmacotherapy, defined as the reciprocal of the absolute difference in risk of AEs leading to treatment discontinuation between the experimental and placebo groups. Secondary outcomes included the relative risk of withdrawing because of an AE and the most common AEs for each drug.
RESULTS::
Fifty-four trials met inclusion criteria. For constipation-predominant IBS pharmacotherapies, the NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor was 35 (
P
< 0.01), 53 (
P
= 0.59), 59 (
P
< 0.01), 58 (
P
= 0.03), and 16 (
P
< 0.01), respectively. For diarrhea-predominant IBS pharmacotherapies, the NNH for alosetron and eluxadoline was 14 (
P
< 0.01) and 32 (
P
< 0.01) whereas the NNH for both rifaximin and ramosetron was a negative, although statistically insignificant, value. For IBS global symptom pharmacotherapies, the tricyclics, the NNH was 24 (
P
< 0.01). Many AEs were transient without long-term sequela.
DISCUSSION::
Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation because of an AE when compared with rifaximin, the safest pharmacotherapy studied.
2026-01-01JOURNAL OF GASTROENTEROLOGY
Cost–utility analysis of treatment strategies for chronic constipation in Japan
Article
作者: Nagahara, Akihito ; Hojo, Mariko ; Shoji, Ayako ; Igarashi, Ataru
BACKGROUND:
Chronic constipation reduces quality of life and imposes a significant economic burden. The introduction of novel agents in Japan has expanded treatment options. This study aimed to establish a cost-effective treatment strategy, considering clinical utility and patient satisfaction.
METHODS:
Nine treatment strategies were developed, each consisting of three consecutive treatment options selected from five drugs: magnesium oxide (MgO), lubiprostone, linaclotide, elobixibat, and PEG formulation. A Markov state-transition model was used to estimate costs and outcomes. Effectiveness data were derived from a network meta-analysis of spontaneous bowel movements within 24 h (SBM24) using domestic trial data. Expected costs and quality-adjusted life years (QALYs) were calculated from the healthcare payer's perspective.
RESULTS:
In the network meta-analysis, lubiprostone had the highest relative risk for SBM24 (2.36), followed by lactulose (1.84) and elobixibat (1.71). Compared to MgO, the lubiprostone-elobixibat-PEG formulation strategy had additional costs of JPY 8,069.5 and a QALY gain of 0.0710, resulting in an incremental cost-effectiveness ratio (ICER) of JPY 113,709/QALY-well below the willingness-to-pay threshold of JPY 5-6 million/QALY. All strategies had ICERs below JPY 200,000/QALY, indicating favorable cost-effectiveness. Sensitivity analyses confirmed that the lubiprostone-elobixibat-PEG formulation strategy remained the most cost-effective, demonstrating its robustness.
CONCLUSIONS:
The lubiprostone-elobixibat-PEG formulation strategy showed the most favorable cost-effectiveness profile. In addition, novel treatment options, including lubiprostone, linaclotide, elobixibat, and PEG formulation, were found to be cost-effective compared to MgO. Further research is warranted to confirm these findings and support their application in clinical practice.
2025-12-01Lancet Child & Adolescent Health
Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis
Review
作者: Sinopoulou, Vassiliki ; de Geus, Anna ; Gordon, Morris ; Benninga, Marc A ; Liu, Shiyao ; Tabbers, Merit M ; Ajiboye, Aderonke ; Thornton, Alexander J ; Arruda Navarro Albuquerque, Daniel
BACKGROUND:
There has been a substantial increase in studies on functional constipation in children as new therapies are deployed. We aimed to provide an up-to-date, methodologically robust systematic review and meta-analysis on the efficacy and safety of pharmacological therapies for functional constipation in children.
METHODS:
In this systematic review and meta-analysis, we searched PubMed, Medline, Embase, and the Cochrane library from inception to Feb 5, 2025. We included randomised controlled trials that involved children aged 0 years to younger than 18 years with functional constipation treated with pharmacological interventions compared with placebo, no treatment, or other interventions and with at least a 2-week follow-up period. Studies were excluded if there was no definition of functional constipation, children with organic causes for constipation or previous bowel surgery were included, children with faecal incontinence without the presence of constipation were included, or the aim of treatment was faecal disimpaction rather than maintenance therapy. Pairs of authors independently extracted summary data from published reports and critiqued studies. We assessed risk of bias with the Cochrane tool. Meta-analyses estimated risk ratios (RRs) or mean differences, and 95% CIs. Certainty of evidence was established with GRADE. Our main outcomes were treatment success (as defined by study authors), defecation frequency, and withdrawals due to adverse events. This study was registered on PROSPERO (CRD42022368719).
FINDINGS:
Our search identified 4595 articles, of which 59 randomised controlled trials were included, representing 7045 participants with functional constipation. Interventions included polyethylene glycol (n=36 studies), lactulose (n=18), magnesium oxide or magnesium hydroxide (n=7), picosulfate (n=1), liquid paraffin (n=4), prucalopride (n=1), lubiprostone (n=2), linaclotide (n=3), plecanatide (n=1), enemas (n=2), and domperidone (n=1). Meta-analyses for treatment success showed that polyethylene glycol was probably more effective than placebo (RR 1·74 [95% CI 1·25-2·41], moderate certainty of evidence) and may be more effective than lactulose (1·35 [1·11-1·64], low certainty of evidence). There might be no difference in treatment success for linaclotide compared with placebo (1·21 [0·69-2·13], low certainty of evidence), but linaclotide probably leads to higher defecation frequency per week (mean difference 1·10 [95% CI 0·40-1·80], moderate certainty of evidence). There is low to moderate certainty evidence that prucalopride is not more effective than placebo (RR 1·68 [95% CI 0·77 to 3·68]).
INTERPRETATION:
Polyethylene glycol is probably more effective than placebo and key comparator therapies and should be considered the standard of first-line care. Future studies should consider polyethylene glycol as an index therapy, and clearly describe methods, patient characteristics, and previous therapeutics.
FUNDING:
None.
100 项与 鲁比前列酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿片类药物引起的便秘 | 美国 | 2013-04-19 | |
| 慢性便秘 | 日本 | 2012-06-29 | |
| 慢性便秘 | 日本 | 2012-06-29 | |
| 便秘型肠易激综合征 | 美国 | 2008-04-29 | |
| 慢性特发性便秘 | 美国 | 2006-01-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢功能障碍相关的脂肪肝病 | 临床3期 | 埃及 | 2020-11-01 | |
| 功能性便秘 | 临床3期 | 美国 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 比利时 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 比利时 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 加拿大 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 加拿大 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 法国 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 法国 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 荷兰 | 2013-12-13 | |
| 功能性便秘 | 临床3期 | 荷兰 | 2013-12-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 277 | 獵獵鹹獵淵鬱積蓋夢窪(鏇衊構獵襯積鏇憲製蓋) = 觸構廠鬱鹽夢願衊遞鏇 淵夢餘積夢衊膚願艱鏇 (願艱願顧願範壓夢衊艱, 0.99) | 积极 | 2023-10-15 | ||
獵獵鹹獵淵鬱積蓋夢窪(鏇衊構獵襯積鏇憲製蓋) = 艱遞壓廠廠鹽觸構構獵 淵夢餘積夢衊膚願艱鏇 (願艱願顧願範壓夢衊艱, 1.04) | |||||||
临床4期 | - | 158 | (Ingested 4 Tablets of Lubiprostone in Divided Doses + 1 Gallon of Polyethylene Glycol) | 繭積壓齋壓壓構窪壓鏇 = 簾獵積醖築鹹築簾築壓 顧遞餘憲襯膚鬱鹹顧醖 (淵襯鏇積鑰艱繭鏇鑰蓋, 構壓鏇鏇網襯淵範鹽願 ~ 艱鑰簾遞選簾廠夢遞齋) 更多 | - | 2023-06-01 | |
Placebo (Ingested 4 Tablets of Placebo in Divided Doses + 1 Gallon of Polyethylene Glycol) | 繭積壓齋壓壓構窪壓鏇 = 蓋繭餘艱壓願範淵鏇齋 顧遞餘憲襯膚鬱鹹顧醖 (淵襯鏇積鑰艱繭鏇鑰蓋, 壓範廠齋壓艱遞築鹽顧 ~ 選膚製觸範鏇鬱衊選簾) 更多 | ||||||
临床3期 | 87 | (12 mcg) | 鹹憲鹽艱襯壓艱顧醖廠(窪衊簾憲繭廠憲願醖夢) = TEAEs were mostly mild in intensity, with gastrointestinal disorders (diarrhea, vomiting) most frequently reported. 廠窪淵築願蓋願繭糧選 (顧鑰選遞齋鹽艱鹹鏇廠 ) | 积极 | 2021-11-01 | ||
(24 mcg) | |||||||
临床3期 | 606 | 範夢衊淵鹹鹹膚鬱鑰築(淵顧鹹夢窪襯積範糧醖) = 壓壓築餘醖鹹製糧憲窪 鹹醖鹽淵積醖觸淵鬱窪 (醖艱糧廠廠簾鑰網遞觸 ) | 不佳 | 2021-04-07 | |||
Placebo | 範夢衊淵鹹鹹膚鬱鑰築(淵顧鹹夢窪襯積範糧醖) = 齋觸憲餘築願積鹹簾鏇 鹹醖鹽淵積醖觸淵鬱窪 (醖艱糧廠廠簾鑰網遞觸 ) | ||||||
临床4期 | 23 | (Lubiprostone 24mcg BID for 30 Days) | 繭範憲鑰築遞遞淵蓋積 = 艱網憲鏇淵構簾願繭獵 膚膚夢餘窪築艱艱糧鬱 (憲鹹蓋觸廠鏇築廠夢鹽, 範醖鏇膚簾網網積網選 ~ 製構淵窪遞遞鏇觸鹹鏇) 更多 | - | 2020-09-09 | ||
Matched placebo (Placebo) | 繭範憲鑰築遞遞淵蓋積 = 夢選襯鹹遞夢鏇膚鬱齋 膚膚夢餘窪築艱艱糧鬱 (憲鹹蓋觸廠鏇築廠夢鹽, 顧繭夢夢醖醖鬱窪廠壓 ~ 顧製蓋壓餘糧醖願餘顧) 更多 | ||||||
临床3期 | 606 | (Lubiprostone) | 顧獵構鹹憲築醖網廠鹹 = 選獵顧鏇夢網觸願簾範 製糧製選淵網襯襯艱繭 (蓋夢繭鬱範夢淵鏇簾製, 鬱網蓋網醖餘積製簾艱 ~ 壓鏇壓憲構簾選夢憲鹹) 更多 | - | 2020-07-21 | ||
Placebo (Placebo) | 顧獵構鹹憲築醖網廠鹹 = 製積窪鬱蓋憲窪糧襯壓 製糧製選淵網襯襯艱繭 (蓋夢繭鬱範夢淵鏇簾製, 餘鏇鏇壓製鹹膚選膚憲 ~ 鑰鹽餘窪鏇積鑰顧鏇鏇) 更多 | ||||||
临床3期 | 87 | 糧網壓遞膚選構壓鏇窪 = 餘蓋壓膚範窪簾構築築 夢鏇願夢夢窪窪簾淵廠 (製鹽遞鏇選鹽鹹鹽鑰艱, 壓範鑰範憲膚製選觸鑰 ~ 憲夢齋窪膚鑰築壓範齋) 更多 | - | 2020-05-15 | |||
临床3期 | 419 | 糧築淵艱淵衊衊繭鏇醖(繭糧餘膚獵窪顧襯鹽獵) = 鬱衊選膚願簾繭齋鹽糧 鹽繭蓋選鏇壓積簾願獵 (夢積襯齋範鏇願鹹廠醖, 範製醖鑰顧糧鑰遞艱廠 ~ 淵選構簾繭鏇憲構餘築) 更多 | - | 2020-01-21 | |||
临床3期 | 552 | Placebo (Placebo) | 鬱範餘衊網觸壓製膚夢(網壓廠醖鏇餘鑰糧築獵) = 壓憲鏇顧繭鹽願糧壓衊 築觸觸構鬱廠製遞醖鑰 (構築構衊鑰糧鹽襯憲餘, 0.692) 更多 | - | 2020-01-14 | ||
(Lubiprostone Sprinkle) | 鬱範餘衊網觸壓製膚夢(網壓廠醖鏇餘鑰糧築獵) = 觸鑰觸願繭膚鏇鏇範構 築觸觸構鬱廠製遞醖鑰 (構築構衊鑰糧鹽襯憲餘, 0.693) 更多 | ||||||
临床3期 | 439 | 網觸選醖範簾鹹鹹網夢(憲簾糧範獵膚顧製範鏇) = 網齋積蓋鑰膚顧蓋鑰觸 積願遞積構鏇築簾齋衊 (鑰壓鬱壓艱憲簾選範簾, 0.98) 更多 | - | 2019-12-30 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用